An ex-vivo Angiogenesis Assay as a Screening Method for Natural Compounds and Herbal Drug Preparations

Abstract

Angiogenesis is a fundamental component of complex biological processes, including oncogenesis. The aim of this work was to optimise and validate an ex-vivo angiogenesis assay as a quantitative (PC image) biological method for testing promising natural compounds and herbal drug preparations for their pro-/anti-angiogenic activity. The bioassay is based on the principle of wound healing and quantifies the effect of angiogenic agents on neovessel outgrowth of human placental vessels embedded in a three-dimensional fibrin matrix. The assay was validated by using known, well characterised pro- and anti-angiogenic effectors (basic fibroblast growth factor and carboxyamidotriazole, respectively), and an angiogenesis inhibitor of plant origin (green tea leaves extract) was used as a reference product to demonstrate the applicability of the assay for plant extracts. Other standardised plant extracts prepared from olive tree leaves and horse chestnut seeds were tested for their angiogenic potential, but showed only slight inhibitory or no activity, respectively. The results presented here indicate that this human ex-vivo angiogenic assay is ”ready to use” for screening of herbal drug preparations and pure compounds.

Key words

Angiogenesis - ex vivo assay - Camellia sinensis - green tea - Olea europaea - olive tree - Aesculus hippocastanum - horse chestnut - endothelial outgrowth - validation - natural compounds - herbal drug preparations

References

• 1 Folkman J. Clinical applications of research in angiogenesis.  N Eng J Med. 1995;  333 1757-63
• 2 Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A. et al . Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: Correlation with proliferation.  Hum Pathol. 2002;  33 863-70
• 3 Gimbrone Jr M A, Cotran R S, Leapman S B, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea.  J Natl Cancer Inst. 1974;  52 413-27
• 4 Andrade S P, Fan T P, Lewis G P. Quantitative in vivo studies in angiogenesis in a rat sponge model.  Br J Exp Pathol. 1987;  68 755-66
• 5 Folkman J. Tumor angiogenesis.  Adv Cancer Res. 1974;  19 331-58
• 6 Vailhé B, Vittet D, Feige J -J. In vitro models of vasculogenesis and angiogenesis.  Lab Invest. 2001;  81 439-52
• 7 Nicosia R F, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta.  Lab Invest. 1990;  63 115-55
• 8 Masson V, Devy L, Grignet-Debrus C h, Bernt S, Bajou K, Blacher S, Roland G, Chang Y, Fong T, Carmeliet P, Foidart J -M, Noël A. Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis.  Biol Proceed Online. 2002;  4 24-31
• 9 Brown K, Maynes S, Bezos A, Maguire D J, Ford M D, Parish C R. A novel in vitro assay for human angiogenesis.  Lab Invest. 1996;  75 539-55
• 10 Sahni A, Francis C W. VEGF binds to fibrinogen and fibrin and stimulates endothelial cell proliferation.  Blood. 2000;  96 3772-8
• 11 Watson J C, Redmann J G, Meyers M O, AlperinLea R C, Gebhardt B M, Delcarpio J B, Woltering E A. Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate.  Surgery. 1997;  122 508-14
• 12 Alessandri G, Girelli M, Taccagni G, Colombo A, Nicosia R, Caruso A, Baronio M, Pagano S, Cova L, Parati E. Human vasculogenesis ex vivo: embryonal aorta as a tool for isolation of endothelial cell progenitors.  Lab Invest. 2001;  81 875-85
• 13 Conn G, Soderman D D, Schaeffer M T, Wile M, Hatcher V B, Thomas K A. Purification of a glycoproein vascular endothelial cell mitogen from a rat glioma-derived cell line.  Proc Natl Acad Sci USA. 1990;  87 1323-7
• 14 Kohn E C, Felder C C, Jacobs W, Holmes K A, Day A, Freer R, Liotta L A. Structure function analysis of signal and growth inhibition by carboxyamidotriazole, CAI.  Cancer Res. 1997;  54 935-42
• 15 Bikfalvi A, Klein S, Pintucci G, Rifkin D B. Biological roles of fibroblast growth factor-2.  Endocr Rev. 1997;  18 26-45
• 16 Basilico C, Moscatelli D. The FGF family of growth factors and oncogenesis.  Adv Cancer Res. 1992;  59 115-65
• 17 Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking tea among a Japanese population.  Prev Med. 1997;  26 769-75
• 18 Cao Y, Cao R. Angiogenesis inhibited by drinking tea.  Nature. 1999;  398 381
• 19 Kojima-Yuasa A, Jin Hua J, Kennedy D O, Matsui-Yuasa I. Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors.  Life Sci. 2003;  93 1299-313
• 20 Lamy S, Gingras D, Béliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation.  Cancer Res. 2002;  62 381-5
• 21 Jankun J, Selman S H, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer.  Nature. 1997;  387 561
• 22 Maeda-Yamamoto M, Kawahara H, Tahara N, Tsuji K, Hara Y, Isemura M. Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT 1080 cells.  J Agric Food Chem. 1999;  47 2350-4
• 23 Okabe S, Suganuma M, Hayashi M, Sueoka E, Komori A, Fujiki H. Mechanisms of growth inhibition of human lung cancer cell line, PC-9, by tea polyphenols.  Int J Cancer. 1997;  88 639-43
• 24 Carluccio M A, Sicuella L, Ancora M A, Massaro M, Scoditti E, Storelli C, Visioli F, Distante A, De Caterina R. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals.  Arterioscler Thromb Vasc Biol. 2003;  23 622-9
• 25 Sirtori C E. Aescin: Pharmacology, pharmacokinetics and therapeutic profile.  Pharmacol Res. 2001;  44 183-93